Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing_NewsRoom_pulnovomed,帕母医疗
Summary
Pulnovo Medical closed nearly $100 million in Series C financing led by Qiming Venture Partners and Lilly Asia Ventures, with participation from OrbiMed and Gaorong Capital. The company plans to use the capital to expand global clinical trials, grow international operations, and advance strategic initiatives. Pulnovo Medical develops PADN, a minimally invasive pulmonary artery denervation technology for pulmonary hypertension and heart failure. The company says the financing will support upcoming FDA trials and continued commercialization across global markets.
Funding
Amount
$100.0M
Total raised
Date
March 3, 2025
Announcement date
Investors
Lilly Asia Ventures, Qiming Venture Partners, OrbiMed, Gaorong Capital
Lead investors
Company
pulnovomed.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected